Company / Working Capital
Summit Therapeutics Inc. Working Capital History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$647.3M
FY2025
5-year range
$71.7M / $647.3M
FY2021-FY2025
Trend
+69.4%
vs FY2024
Sector context
#70 of 213
Health Care
What the data says
At $647M, Summit Therapeutics Inc.'s working capital ranks #70 of 213 in the Health Care sector. Improved from $169M to $647M over the past 2 years.
Based on SEC 10-K filings.
$647M in FY2025 with a 5-year CAGR of +57.0%.
Improved from $169M to $647M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +1.6%
- 5-Year CAGR
- +57.0%
- 10-Year CAGR
- -
Sector benchmark
#70 of 213 in Health CareTop 33% of 213This company $647.3M Sector average $934.6M
▼
-30.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +57.0%, indicating consistent growth.
- In FY2025, working capital increased 69.4% year-over-year.
- Ranks #70 out of 213 companies in the Health Care sector.
- Lowest working capital in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $647.3M | +69.4% |
| FY2024 | $382.0M | +125.6% |
| FY2023 | $169.3M | -72.6% |
| FY2022 | $617.9M | +762.0% |
| FY2021 | $71.7M | +5.8% |
| FY2020 | $67.8M | +2.9% |
| FY2019 | $65.9M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026